All

Results: 16501-16512 of 71498

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

PR Newswire associated0

Wialon Announces Top 10 GPS Hardware Manufacturers for 2025

PR Newswire associated0

From Presentation to Full-Service Reception: AiMOGA Robot Demonstrates "Human Assistant" Capabilities at the 2025 Chery Global Innovation Conference

PR Newswire associated0

China's Sichuan Extends Cultural Tourism Invitations at Global Landmarks

PR Newswire associated0

One Heung Kong released the White Paper on Global Sustainable and Healthy Living Environments jointly with other institutions

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025

SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025

Kolibri Global Energy Inc. Provides Update Regarding Information Circular Disclosure

PR Newswire associated0

The 138th Canton Fair Builds Seamless Global Trade Platform with Service and Experience Upgrades

PR Newswire associated0

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event